HotSpot Therapeutics

Data updated Nov 20, 2026Full reportReport a mistake

Facts

as of Nov 20, 2026

Pioneering a new class of allosteric medicines for the treatment of autoimmune disease. At HotSpot Therapeutics, we are pioneering a new approach to allosteric drug discovery by unlocking the on/off switches on proteins called "natural hotspots" to enable differentiated medicines for patients.

Employees
201-500estimated range
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Products

Products →

HotSpot Therapeutics has 1 clinical trials on record, 1 under way.

Clinical trials
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
phase 2 · under way · 77 participants · Solid Tumor, Adult; Relapsed Cancer; Refractory Cancer
Mar 2023
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Lists and programmes
Hurun Global Gazelles
2025 · HealthTech
Sources: the outlets named on each headline, each story once

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices